Growth Metrics

Silence Therapeutics (SLN) Assets Average: 2019-2025

Historic Assets Average for Silence Therapeutics (SLN) over the last 3 years, with Sep 2025 value amounting to $156.0 million.

  • Silence Therapeutics' Assets Average rose 17.83% to $156.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.0 million, marking a year-over-year increase of 17.83%. This contributed to the annual value of $161.0 million for FY2024, which is 119.46% up from last year.
  • Latest data reveals that Silence Therapeutics reported Assets Average of $156.0 million as of Q3 2025, which was down 10.99% from $175.3 million recorded in Q2 2025.
  • Silence Therapeutics' 5-year Assets Average high stood at $194.0 million for Q1 2025, and its period low was $8.4 million during Q1 2022.
  • For the 3-year period, Silence Therapeutics' Assets Average averaged around $112.9 million, with its median value being $138.3 million (2024).
  • Data for Silence Therapeutics' Assets Average shows a peak YoY surged of 742.71% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Silence Therapeutics' Assets Average stood at $17.0 million in 2021, then reached $8.4 million in 2022, then spiked by 173.37% to $72.4 million in 2023, then spiked by 124.78% to $162.7 million in 2024, then rose by 17.83% to $156.0 million in 2025.
  • Its Assets Average stands at $156.0 million for Q3 2025, versus $175.3 million for Q2 2025 and $194.0 million for Q1 2025.